Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
| Title: | Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use |
|---|---|
| Patent Number: | 7,026,457 |
| Publication Date: | April 11, 2006 |
| Appl. No: | 09/973025 |
| Application Filed: | October 10, 2001 |
| Abstract: | The present invention relates to a method for purifying recombinant HCV single or specific oligomeric envelope proteins selected from the group consisting of E1 and/or E1/E2 characterized in that upon lysing the transformed host cells to isolate the recombinantly expressed protein a disulphide bond cleavage or reduction step is carried out with a disulphide bond cleavage agent. The present invention also relates to a composition isolated by such a method. The present invention also relates to the diagnostic and therapeutic application of these compositions. Furthermore, the invention relates to the use of HCV E1 protein and peptides for prognosing and monitoring the clinical effectiveness and/or clinical outcome of HCV treatment. |
| Inventors: | Maertens, Geert (Bruges, BE); Bosman, Fons (Opwijk, BE); De Martynoff, Guy (Waterloo, BE); Buyse, Marie Ange (Merelbeke, BE) |
| Assignees: | Innogenetics N.V. (Ghent, BE) |
| Claim: | 1. An isolated E2 specific monoclonal antibody, said antibody specifically binding to at least one region within a domain spanning amino acids 416-650 or 655-809 of the hepatitis C virus polyprotein. |
| Claim: | 2. An isolated monoclonal antibody binds to the same epitope as the E2 specific monoclonal antibody according to claim 1 . |
| Claim: | 3. The monocional antibody according to claim 1 or 2 which has been produced from a mammal immunized with a composition comprising purified recombinant HCV single or specific oligomeric recombinant E2 envelope proteins. |
| Claim: | 4. The monoclonal antibody according to claim 3 wherein said recombinant HCV E2 envelope proteins are produced by a recombinant mammalian cell. |
| Claim: | 5. The monoclonal antibody of claim 4 wherein said mammalian cell is infected with recombinant vaccinia virus carrying DNA for expressing said HCV E2 envelope proteins. |
| Claim: | 6. The monoclonal antibody according to claim 3 wherein said recombinant HCV E2 envelope proteins are produced by a recombinant yeast cell. |
| Claim: | 7. The monoclonal antibody according to claim 3 wherein said recombinant HCV E2 envelope proteins are the expression product of at least one of the following recombinant vectors: a) a recombinant vector comprising a vector sequence, a prokaryotic, eukaryotic or viral promoter sequence followed by a nucleotide sequence encoding said single or specific oligomeric E2 protein; b) a recombinant vector according to (a), with said nucleotide sequence being characterized further in that in encodes a single HCV E2 protein starting in the region between amino acid positions 290 and 406 and ending in the region between amino acid positions 600 and 820; c) a recombinant vector according to (b), with said nucleotide sequence being characterized further in that it ends at any of amino acid positions 623, 650, 661, 673, 710, 715, 720, 746 or 809; d) a recombinant vector according to any one of (b)-(c), said nucleotide sequence further comprising a 5′-terminal ATG codon and a 3′-terminal stop codon; and e) a recombinant vector according to any one of (b)-(d) further comprising a factor Xa cleavage site and/or 3 to 10 histidine codons positioned 3′-terminally to said nucleotide sequence. |
| Claim: | 8. An isolated antibody of claim 3 which is an E2 specific monoclonal antibody. |
| Claim: | 9. The isolated protein of claim 3 wherein said E2 protein is at least 90% pure. |
| Claim: | 10. The isolated protein of claim 3 wherein said E2 protein is at least 95% pure. |
| Claim: | 11. The isolated protein of claim 3 wherein said E2 protein is at least 97% pure. |
| Claim: | 12. The isolated antibody of claim 3 wherein said E2 protein is at least 97% pure. |
| Claim: | 13. The isolated antibody of claim 3 wherein said E2 protein is at least 99% pure. |
| Claim: | 14. The monoclonal antibody according to claim 1 or 2 which has been produced from a mammal immunized with a composition comprising at least one purified recombinant HCV single or specific oligomeric recombinant E2 envelope protein. |
| Claim: | 15. Kit for determining the presence of HCV antigens present in a biological sample, comprising: at least one E2 specific monoclonal antibody according to claim 1 or 2 , a buffer or components necessary for producing the buffer enabling binding reaction between these antibodies and the HCV antigens present in said biological sample, a means for detecting the immune complexes formed in the preceding binding reaction. |
| Claim: | 16. The isolated E2 specific monoclonal antibody secreted by the hybridoma cell line deposited Dec. 3, 1998 with the European Collection or Cell Cultures and assigned the accession number 98031215 or a hybridoma cell line selected from deposit accession numbers DSM ACC 2616 or DSM ACC 2615, each of which were deposited Sep. 10, 2003 with DSMZ. |
| Claim: | 17. An isolated monoclonal antibody which binds to the same epitope as the E2 specific monoclonal antibody of claim 16 . |
| Claim: | 18. An isolated E2 specific monoclonal antibody which specifically binds to a region in the E2 domain spanning an amino acid segment selected from the group consisting of 409-428 (SEQ ID NO:73), 427-446 (SEQ ID NO: 74), 439-458 (SEQ ID NO:75), 451-470 (SEQ ID NO:76), 463-482 (SEQ ID NO:77), 478-494 (SEQ ID NO:78), 487-506 (SEQ ID NO:79), 499-518 (SEQ ID NO:80), 511-530 (SEQ ID NO:81), 523-542 (SEQ ID NO:82), 547-566 (SEQ ID NO:83), 559-578 (SEQ ID NO: 84), 571-590 (SEQ ID NO:85), 583-602 (SEQ ID NO:86), 595-614 (SEQ ID NO:87), 607-626 (SEQ ID NO:88), 619-638 (SEQ ID NO:89), 631 -650 (SEQ ID NO:90) and 655-674 (SEQ ID NO:92). |
| Current U.S. Class: | 5303/883 |
| Patent References Cited: | 5308750 May 1994 Mehta et al. 5514539 May 1996 Bukh et al. 5582968 December 1996 Wang 5610009 March 1997 Wantanabe et al. 5670152 September 1997 Weiner et al. 5747239 May 1998 Wang 5830691 November 1998 Miyamura et al. 5866139 February 1999 Brechot et al. 5871962 February 1999 Bukh et al. 5919454 July 1999 Brechot 6074846 June 2000 Ralston et al. 6150134 November 2000 Maertens et al. 6183949 February 2001 Seidel 6245503 June 2001 Maertens et al. 0388232 September 1990 0388232 September 1990 0537626 April 1993 0585549 March 1994 0569537 June 1998 1 211 315 June 2002 2212511 July 1989 PCT/US91/08272 January 1991 PCT/IT92/00081 January 1992 PCT/US92/07189 January 1992 WO 92/13892 August 1992 PCT/US93/00907 January 1993 WO 93/04888 March 1993 WO 93/06247 April 1993 WO 93/18054 September 1993 WO93/18054 September 1993 WO 94/01778 January 1994 |
| Other References: | Petit et al. J. Biol. Chemistr. 2003, vol. 278, pp. 44385-44392. cited by examiner Matsuura et al. J. Virol. 1992, 66, No. 3, pp. 1425-1431. cited by examiner Kaito et al. J. Gene. Virol. 1994, vol. 75, pp. 1755-1760. cited by examiner Choo, et al., “Vaccination of Chimpanzees Against . . . Hepatitis C Virus”, Proc. Natl. Acad. Sci., 1994, pp. 1294-1298. cited by other Lanford, et al., “Analysis of Hepatitis C Virus . . . ”, Virology 197, pp. 225-235, 1993. cited by other Nishihara, et al., Gene 129, 1993, 207-214. cited by other Ralson, et al., J. Virol. 67, 1993, 6753-6761. cited by other Kohara, et al., J. Gen. Virol. 73, 1992, 2313-2318. cited by other Choo, et al., Proc. Natl. Acad. Sci. USA 88, 1991, 2451-2455. cited by other Farci, Science, vol. 258, 1992, 135-140. cited by other |
| Assistant Examiner: | Li, Bao Qun |
| Primary Examiner: | Housel, James |
| Attorney, Agent or Firm: | Nixon & Vanderhye P.C. |
| Accession Number: | edspgr.07026457 |
| Database: | USPTO Patent Grants |
| Language: | English |
|---|